Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:CRONNASDAQ:FOMXNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.41▼$9.18$611.50M2.21816,251 shs554,788 shsCRONCronos Group$2.04+2.0%$1.96$1.60▼$2.54$786.79M1.031.35 million shs1.94 million shsFOMXMenlo Therapeutics$2.99$2.99$1.97▼$4.84$184.12M1.66518,350 shsN/ATLRYTilray Brands$0.53+9.4%$0.43$0.35▼$2.15$542.20M1.8229.98 million shs43.04 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%0.00%+209.65%CRONCronos Group0.00%+7.37%+6.81%+19.30%-12.07%FOMXMenlo Therapeutics0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands0.00%+32.52%+36.79%-10.33%-69.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex3.2023 of 5 stars3.50.00.04.00.00.01.9CRONCronos Group2.2709 of 5 stars0.05.00.00.01.90.02.5FOMXMenlo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray Brands1.7885 of 5 stars3.11.00.00.02.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideCRONCronos Group 0.00N/AN/AN/AFOMXMenlo Therapeutics 0.00N/AN/AN/ATLRYTilray Brands 2.25Hold$1.92260.95% UpsideCurrent Analyst Ratings BreakdownLatest FOMX, CRON, CDXC, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TLRYTilray BrandsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilray BrandsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00CRONCronos Group$117.61M6.69$0.00 per share4,384.08$2.90 per share0.70FOMXMenlo Therapeutics$3.60M51.15N/AN/A$1.70 per share1.76TLRYTilray Brands$788.94M0.68N/AN/A$4.14 per share0.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ACRONCronos Group$41.08M$0.1315.6968.00N/A39.69%-0.07%-0.07%8/6/2025 (Estimated)FOMXMenlo Therapeutics-$74.16M-$1.70N/AN/AN/AN/A-100.58%-81.39%N/ATLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest FOMX, CRON, CDXC, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/8/2025Q3 2025TLRYTilray Brands-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AFOMXMenlo TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35CRONCronos GroupN/A27.8026.75FOMXMenlo Therapeutics0.245.725.72TLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%CRONCronos Group8.71%FOMXMenlo Therapeutics46.46%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%CRONCronos Group7.30%FOMXMenlo Therapeutics2.95%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableCRONCronos Group450385.68 million357.53 millionOptionableFOMXMenlo Therapeutics8061.58 millionN/AOptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableFOMX, CRON, CDXC, and TLRY HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Stock Rating Lowered by Wall Street ZenJuly 5 at 2:59 AM | marketbeat.comTilray Brands Sees Unusually Large Options Volume (NASDAQ:TLRY)July 5 at 2:11 AM | americanbankingnews.comTilray Brands (NASDAQ:TLRY) Stock Price Up 9.4% - Still a Buy?July 4 at 12:13 PM | marketbeat.comHere’s why the Tilray Brands stock price has implodedJuly 3 at 5:07 PM | invezz.comIStock Traders Buy Large Volume of Tilray Brands Call Options (NASDAQ:TLRY)July 3 at 2:09 PM | marketbeat.comCannabis Stocks To Keep An Eye On - July 3rdJuly 3 at 1:46 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading 4.1% Higher - Here's WhyJuly 2, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 1.3% - Should You Sell?July 1, 2025 | marketbeat.comBeers, Live Music, Hot Dogs and Fireworks: Everything You Need for an Epic 4th Of July CelebrationJuly 1, 2025 | financialpost.comFBreckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles TolandJuly 1, 2025 | financialpost.comFBreckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles TolandJuly 1, 2025 | globenewswire.comTLRY - Tilray Brands Inc News - MorningstarJune 28, 2025 | morningstar.comMTilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for InvestorsJune 27, 2025 | zacks.comTilray Brands (NASDAQ:TLRY) Shares Up 3.9% - Should You Buy?June 26, 2025 | marketbeat.comTilray Brands (NasdaqGS:TLRY) Advances Medical Cannabis Research With New Bioavailability StudyJune 26, 2025 | finance.yahoo.comTilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD FormulationsJune 26, 2025 | finance.yahoo.comMontauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider FoundationJune 26, 2025 | globenewswire.comTLRY Stock - Tilray Brands Inc Stock Price Quote - XTSE - MorningstarJune 26, 2025 | morningstar.comMHere Is A List Of 3 Canadian Marijuana Stocks To Watch 2025June 25, 2025 | marijuanastocks.comMTilray Medical Launches “Good Supply” Cannabis Brand in GermanyJune 25, 2025 | insidermonkey.comTilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic UseJune 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeMicron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingBy Thomas Hughes | June 26, 2025View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingMicron’s Big Q3 Drives Applied Materials’ Bullish OutlookBy Leo Miller | July 3, 2025View Micron’s Big Q3 Drives Applied Materials’ Bullish OutlookMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment FOMX, CRON, CDXC, and TLRY Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Cronos Group NASDAQ:CRON$2.04 +0.04 (+2.00%) Closing price 07/3/2025 03:16 PM EasternExtended Trading$2.04 0.00 (-0.25%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Menlo Therapeutics NASDAQ:FOMXFoamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.Tilray Brands NASDAQ:TLRY$0.53 +0.05 (+9.44%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.54 +0.00 (+0.75%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
